: Several studies have shown the efficacy of new disease-modifying therapies in slowing down type II SMA progression using the Hammersmith Functional Motor Scale Expanded (HFMSE). This research aims to enhance understanding of activity changes across age groups post-nusinersen treatment using shift analysis, compared with untreated individuals. Retrospective data from the, international SMA consortium (iSMAc) dataset were analyzed, assessing individual item changes over 12 months. Shift analysis was used to determine the gain or loss of abilities, defining "gain" as a positive change between scores from 0 to either 1 or 2 and "loss" as a negative change from either 2 or 1 to 0. The cohort included 130 SMA II patients who underwent 12-month assessments from their first nusinersen dose, with age range between 0.6 and 49.6 years. One-third of the entire cohort experienced at least a loss in one activity, while 60% experienced a gain, particularly notable in children aged 2.5 to 5 years and 5 to 13 years. Overall, the study demonstrates a positive impact of nusinersen treatment on SMA II patients, showing a trend of increased activity gains and decreased probability of ability loss across different age groups.
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA / Coratti, G.; Civitello, M.; Rohwer, A.; Salmin, F.; Glanzman, A. M.; Montes, J.; Pasternak, A.; De Sanctis, R.; Young, S. D.; Duong, T.; Mizzoni, I.; Milev, E.; Sframeli, M.; Morando, S.; Albamonte, E.; D'Amico, A.; Brolatti, N.; Pane, M.; Scoto, M.; Messina, S.; Hirano, M.; Zolkipli-Cunningham, Z.; Darras, B. T.; Bertini, E.; Bruno, C.; Sansone, V. A.; Day, J.; Baranello, G.; Pera, M. C.; Muntoni, F.; Finkel, R.; Mercuri, E.. - In: NEUROMUSCULAR DISORDERS. - ISSN 0960-8966. - 41:(2024), pp. 42-50. [10.1016/j.nmd.2024.05.003]
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA
Pera M. C.;
2024-01-01
Abstract
: Several studies have shown the efficacy of new disease-modifying therapies in slowing down type II SMA progression using the Hammersmith Functional Motor Scale Expanded (HFMSE). This research aims to enhance understanding of activity changes across age groups post-nusinersen treatment using shift analysis, compared with untreated individuals. Retrospective data from the, international SMA consortium (iSMAc) dataset were analyzed, assessing individual item changes over 12 months. Shift analysis was used to determine the gain or loss of abilities, defining "gain" as a positive change between scores from 0 to either 1 or 2 and "loss" as a negative change from either 2 or 1 to 0. The cohort included 130 SMA II patients who underwent 12-month assessments from their first nusinersen dose, with age range between 0.6 and 49.6 years. One-third of the entire cohort experienced at least a loss in one activity, while 60% experienced a gain, particularly notable in children aged 2.5 to 5 years and 5 to 13 years. Overall, the study demonstrates a positive impact of nusinersen treatment on SMA II patients, showing a trend of increased activity gains and decreased probability of ability loss across different age groups.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
